Compare Essex Property Trust, Inc. (ESS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Essex Property Trust, Inc. trades at $297.74 (market cap $18.82B), while Regeneron Pharmaceuticals Inc trades at $675.74 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.7× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.54%). Which is the better fit depends on your goals.
| ESS | REGN | |
|---|---|---|
Market Cap | $18.82B | $69.66B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $812.27 |
52-Week Low | $239.61 | $542.52 |
Enterprise Value | $25.54B | $63.61B |
Dividend Yield | 3.54% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Essex Property Trust (ESS) trades at $293.32, down 1.61% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 30.03% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and inclusion in the Russell Microcap Index, reflecting positive momentum.
The outlook for ESS is cautiously optimistic, driven by robust West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts maintain a mixed consensus with a $294.25 price target, suggesting limited near-term upside from current levels amid balanced sentiment.
Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.
Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
